O’Melveny’s Representation of CTI in Fundraising Noted in the Deal

October 27, 2015 The Deal’s October 27, 2015, article, “CTI BioPharma Raising US$50 Million to Commercialize Cancer Drug,” noted that O’Melveny & Myers served as a legal advisor to CTI in its agreement to sell convertible preferred shares in its second private investment in public equity financing in less than a month.